BioNTech SE (BNTX) Stock Forecast & Price Target

Compare

4,734 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BNTX Analyst Ratings

Strong Buy

12 Buy

3 Hold

0 Sell

Based on 15 analysts giving stock ratings to

BioNTech

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BNTX Stock 12 Month Forecast

Average Price Target

$141.57

▲(47.70% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for BioNTech SE in the last 3 months. The average price target is $141.57 with a high forecast of $181.00 and a low forecast of $116.00. The average price target represents a 47.70% change from the last price of $95.85.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"89":"$89","182":"$182","112.25":"$112.3","135.5":"$135.5","158.75":"$158.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":181,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$181.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":141.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$141.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":116,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$116.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[89,112.25,135.5,158.75,182],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,97.39,103.82153846153847,110.25307692307692,116.68461538461538,123.11615384615385,129.5476923076923,135.97923076923075,142.41076923076923,148.84230769230768,155.27384615384614,161.70538461538462,168.1369230769231,174.56846153846152,{"y":181,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,97.39,100.78846153846153,104.18692307692308,107.58538461538461,110.98384615384614,114.38230769230769,117.78076923076922,121.17923076923077,124.5776923076923,127.97615384615384,131.37461538461537,134.77307692307693,138.17153846153846,{"y":141.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,97.39,98.82153846153847,100.25307692307692,101.68461538461538,103.11615384615385,104.5476923076923,105.97923076923077,107.41076923076923,108.84230769230768,110.27384615384615,111.70538461538462,113.13692307692307,114.56846153846153,{"y":116,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":117.2,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.95,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.77,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.29,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.43,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":113.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.34,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.62,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.21,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.39,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$181.00

Average Price Target$141.57

Lowest Price Target$116.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

William Maughan

Clear Street

$181

Buy

88.84%

Upside

Reiterated

12/10/25

Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), CVS Health (CVS)

Robert Burns

H.C. Wainwright

$140

Buy

46.06%

Upside

Reiterated

12/10/25

BioNTech SE: Promising Clinical Trials and Strong Buy Rating Reinforced by Robert BurnsValuation and Risks. We employ a discounted cash flow (DCF)-based valuation approach, using an 8% discount rate and a 2.0% terminal growth rate. Our projected effective tax rate is 28%. These parameters yield a firm value of $35.3B, or a price objective of $140 per share based on 253.1M shares outstanding.

Geoff Meacham

Citi

$145

Buy

51.28%

Upside

Reiterated

12/09/25

Citi Sticks to Their Buy Rating for BioNTech SE (BNTX)

Tazeen Ahmad

Bank of America Securities

$134

Buy

39.80%

Upside

Reiterated

12/09/25

BioNTech's Promising Phase 2 Trial Results for Pumitamig in TNBC Justify Buy Rating

Evan Seigerman

BMO Capital

$143

Buy

49.19%

Upside

Reiterated

12/08/25

BMO Capital Keeps Their Buy Rating on BioNTech SE (BNTX)

Asthika Goonewardene

Truist Financial

―

Buy

―

Reiterated

12/08/25

Analysts Are Bullish on Top Healthcare Stocks: BioNTech SE (BNTX), Icon (ICLR)

Akash Tewari

Jefferies

$151

Buy

57.54%

Upside

Reiterated

12/03/25

Jefferies Sticks to Their Buy Rating for BioNTech SE (BNTX)

Harry Gillis

Berenberg Bank

$150

Buy

56.49%

Upside

Reiterated

11/25/25

Berenberg Bank Remains a Buy on BioNTech SE (BNTX)

Terence Flynn

Morgan Stanley

$134

Buy

39.80%

Upside

Reiterated

11/24/25

Analysts Conflicted on These Healthcare Names: Ascendis Pharma (NASDAQ: ASND), Galapagos (NASDAQ: GLPG) and BioNTech SE (NASDAQ: BNTX)

Cory Kasimov

Evercore ISI

$130

Buy

35.63%

Upside

Reiterated

11/12/25

Evercore ISI Reaffirms Their Buy Rating on BioNTech SE (BNTX)

Mohit Bansal

Wells Fargo

$150

Buy

56.49%

Upside

Reiterated

11/12/25

Analysts' Top Healthcare Picks: Arcturus Therapeutics (ARCT), Edwards Lifesciences (EW)

Eliana Merle

UBS

$115→$117

Hold

22.07%

Upside

Reiterated

11/06/25

UBS Reaffirms Their Hold Rating on BioNTech SE (BNTX)

Yaron Werber

TD Cowen

$120→$116

Hold

21.02%

Upside

Reiterated

11/03/25

TD Cowen Sticks to Its Hold Rating for BioNTech SE (BNTX)

John Newman

Canaccord Genuity

$171

Buy

78.40%

Upside

Reiterated

10/30/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Align Tech (NASDAQ: ALGN), BrightSpring Health Services, Inc. (NASDAQ: BTSG) and BioNTech SE (NASDAQ: BNTX)

Jessica Fye

J.P. Morgan

$121→$120

Hold

25.20%

Upside

Reiterated

10/23/25

Analysts Conflicted on These Healthcare Names: BioNTech SE (NASDAQ: BNTX), Icon (NASDAQ: ICLR) and Innovent Biologics (Other OTC: IVBXF)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

William Maughan

Clear Street

$181

Buy

88.84%

Upside

Reiterated

12/10/25

Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), CVS Health (CVS)

Robert Burns

H.C. Wainwright

$140

Buy

46.06%

Upside

Reiterated

12/10/25

Geoff Meacham

Citi

$145

Buy

51.28%

Upside

Reiterated

12/09/25

Citi Sticks to Their Buy Rating for BioNTech SE (BNTX)

Tazeen Ahmad

Bank of America Securities

$134

Buy

39.80%

Upside

Reiterated

12/09/25

BioNTech's Promising Phase 2 Trial Results for Pumitamig in TNBC Justify Buy Rating

Evan Seigerman

BMO Capital

$143

Buy

49.19%

Upside

Reiterated

12/08/25

BMO Capital Keeps Their Buy Rating on BioNTech SE (BNTX)

Asthika Goonewardene

Truist Financial

―

Buy

―

Reiterated

12/08/25

Analysts Are Bullish on Top Healthcare Stocks: BioNTech SE (BNTX), Icon (ICLR)

Akash Tewari

Jefferies

$151

Buy

57.54%

Upside

Reiterated

12/03/25

Jefferies Sticks to Their Buy Rating for BioNTech SE (BNTX)

Harry Gillis

Berenberg Bank

$150

Buy

56.49%

Upside

Reiterated

11/25/25

Berenberg Bank Remains a Buy on BioNTech SE (BNTX)

Terence Flynn

Morgan Stanley

$134

Buy

39.80%

Upside

Reiterated

11/24/25

Analysts Conflicted on These Healthcare Names: Ascendis Pharma (NASDAQ: ASND), Galapagos (NASDAQ: GLPG) and BioNTech SE (NASDAQ: BNTX)

Cory Kasimov

Evercore ISI

$130

Buy

35.63%

Upside

Reiterated

11/12/25

Evercore ISI Reaffirms Their Buy Rating on BioNTech SE (BNTX)

Mohit Bansal

Wells Fargo

$150

Buy

56.49%

Upside

Reiterated

11/12/25

Analysts' Top Healthcare Picks: Arcturus Therapeutics (ARCT), Edwards Lifesciences (EW)

Eliana Merle

UBS

$115→$117

Hold

22.07%

Upside

Reiterated

11/06/25

UBS Reaffirms Their Hold Rating on BioNTech SE (BNTX)

Yaron Werber

TD Cowen

$120→$116

Hold

21.02%

Upside

Reiterated

11/03/25

TD Cowen Sticks to Its Hold Rating for BioNTech SE (BNTX)

John Newman

Canaccord Genuity

$171

Buy

78.40%

Upside

Reiterated

10/30/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Align Tech (NASDAQ: ALGN), BrightSpring Health Services, Inc. (NASDAQ: BTSG) and BioNTech SE (NASDAQ: BNTX)

Jessica Fye

J.P. Morgan

$121→$120

Hold

25.20%

Upside

Reiterated

10/23/25

Analysts Conflicted on These Healthcare Names: BioNTech SE (NASDAQ: BNTX), Icon (NASDAQ: ICLR) and Innovent Biologics (Other OTC: IVBXF)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioNTech SE

1 Month

xxx

Success Rate

14/25 ratings generated profit

Average Return

+0.90%

reiterated a xxx

rating 18 hours ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 56.00% of your transactions generating a profit, with an average return of +0.90% per trade.

3 Months

xxx

Success Rate

11/25 ratings generated profit

Average Return

+1.03%

reiterated a xxx

rating 18 hours ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 44.00% of your transactions generating a profit, with an average return of +1.03% per trade.

1 Year

Robert BurnsH.C. Wainwright

Success Rate

13/25 ratings generated profit

Average Return

+0.09%

reiterated a buy rating 18 hours ago

Copying Robert Burns's trades and holding each position for 1 Year would result in 52.00% of your transactions generating a profit, with an average return of +0.09% per trade.

2 Years

xxx

Success Rate

10/25 ratings generated profit

Average Return

-3.91%

reiterated a xxx

rating 18 hours ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 40.00% of your transactions generating a profit, with an average return of -3.91% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BNTX Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BNTX has received 33 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. BNTX average Analyst price target in the past 3 months is 141.57.

Each month's total comprises the sum of three months' worth of ratings.

BNTX Financial Forecast

BNTX Earnings Forecast

Next quarter’s earnings estimate for BNTX is -$0.25 with a range of -$2.45 to $0.91. The previous quarter’s EPS was -$0.14. BNTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year BNTX has Performed in-line its overall industry.

BNTX Sales Forecast

Next quarter’s sales forecast for BNTX is $894.50M with a range of $755.69M to $1.27B. The previous quarter’s sales results were $1.77B. BNTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year BNTX has Performed in-line its overall industry.

BNTX Stock Forecast FAQ

What is BNTX’s average 12-month price target, according to analysts?

Based on analyst ratings, BioNTech SE’s 12-month average price target is 141.57.

What is BNTX’s upside potential, based on the analysts’ average price target?

BioNTech SE has 47.70% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BNTX a Buy, Sell or Hold?

BioNTech SE has a consensus rating of Strong Buy which is based on 12 buy ratings, 3 hold ratings and 0 sell ratings.

What is BioNTech SE’s price target?

The average price target for BioNTech SE is 141.57. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $181.00 ,the lowest forecast is $116.00. The average price target represents 47.70% Increase from the current price of $95.85.

What do analysts say about BioNTech SE?

BioNTech SE’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of BNTX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

BioNTech SE (BNTX) Stock Forecast & Price Target

BNTX Analyst Ratings

BNTX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BioNTech SE

BNTX Analyst Recommendation Trends

BNTX Financial Forecast

BNTX Earnings Forecast

BNTX Sales Forecast

BNTX Stock Forecast FAQ

Detailed List of Analyst Forecasts